Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab comb...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Almulla
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immunogenicity IBD infliximab azathioprine vaccine BNT162b2 Medicine R
Acceso en línea:	https://doaj.org/article/6f581808a6e84b749718e82f308ceecb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f581808a6e84b749718e82f308ceecb
record_format	dspace
spelling	oai:doaj.org-article:6f581808a6e84b749718e82f308ceecb2021-11-25T18:02:08ZImmunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study10.3390/jcm102253622077-0383https://doaj.org/article/6f581808a6e84b749718e82f308ceecb2021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5362https://doaj.org/toc/2077-0383Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab combination). Therefore, we sought to evaluate serologic responses to COVID-19 vaccination with the mRNA vaccine, BNT162b2, in patients with IBD receiving infliximab combination therapy compared with healthy participants. Method: This was a multicenter prospective study. Patients with IBD were recruited at the time of attendance at infusion center between 1 August 2021, and 15 September 2021. Our primary outcome were the concentrations of SARS-CoV-2 antibodies 4–10 weeks after vaccination with two doses of BNT162b2 vaccine in patients with IBD taking infliximab combination therapy (study group) compared with a healthy participants group (control group). Both study and control groups were matched for age, sex, and time-since-last-vaccine-dose using optimal pair-matching method. Results: In total, 116 participants were recruited in the study, 58 patients in the study group and 58 in the control group. Median (IQR) IgG concentrations were lower in the study group (99 BAU/mL (40, 177)) than the control group (139 BAU/mL (120, 188)) following vaccination (<i>p</i> = 0.0032). Neutralizing antibodies were also lower in the study group compared with the control group (64% (23, 94) vs. 91% (85, 94), <i>p</i> < 0.001). The median IgA levels in the study group were also significantly lower when compared with the control group (6 U/mL (3, 34) vs. 13 U/mL (7, 30), <i>p</i> = 0.0097). In the study group, the percentages of patients who achieved positive IgG, neutralizing antibody and IgA levels were 81%, 75%, and 40%, respectively. In the control group, all participants (100%) had positive IgG and neutralizing antibody levels while 62% had positive IgA levels. Conclusion: In patients with IBD receiving infliximab combination therapy, SARS-CoV2 IgG, IgA, and neutralizing antibody levels after BNT162b2 vaccination were lower compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.Mohammad ShehabMohamed Abu-FarhaFatema AlrashedAhmad AlfadhliKhazna AlotaibiAbdullah AlsahliThangavel Alphonse ThanarajArshad ChannanathHamad AliJehad AbubakerFahd AlmullaMDPI AGarticleimmunogenicityIBDinfliximabazathioprinevaccineBNT162b2MedicineRENJournal of Clinical Medicine, Vol 10, Iss 5362, p 5362 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunogenicity IBD infliximab azathioprine vaccine BNT162b2 Medicine R
spellingShingle	immunogenicity IBD infliximab azathioprine vaccine BNT162b2 Medicine R Mohammad Shehab Mohamed Abu-Farha Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Jehad Abubaker Fahd Almulla Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
description	Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab combination). Therefore, we sought to evaluate serologic responses to COVID-19 vaccination with the mRNA vaccine, BNT162b2, in patients with IBD receiving infliximab combination therapy compared with healthy participants. Method: This was a multicenter prospective study. Patients with IBD were recruited at the time of attendance at infusion center between 1 August 2021, and 15 September 2021. Our primary outcome were the concentrations of SARS-CoV-2 antibodies 4–10 weeks after vaccination with two doses of BNT162b2 vaccine in patients with IBD taking infliximab combination therapy (study group) compared with a healthy participants group (control group). Both study and control groups were matched for age, sex, and time-since-last-vaccine-dose using optimal pair-matching method. Results: In total, 116 participants were recruited in the study, 58 patients in the study group and 58 in the control group. Median (IQR) IgG concentrations were lower in the study group (99 BAU/mL (40, 177)) than the control group (139 BAU/mL (120, 188)) following vaccination (<i>p</i> = 0.0032). Neutralizing antibodies were also lower in the study group compared with the control group (64% (23, 94) vs. 91% (85, 94), <i>p</i> < 0.001). The median IgA levels in the study group were also significantly lower when compared with the control group (6 U/mL (3, 34) vs. 13 U/mL (7, 30), <i>p</i> = 0.0097). In the study group, the percentages of patients who achieved positive IgG, neutralizing antibody and IgA levels were 81%, 75%, and 40%, respectively. In the control group, all participants (100%) had positive IgG and neutralizing antibody levels while 62% had positive IgA levels. Conclusion: In patients with IBD receiving infliximab combination therapy, SARS-CoV2 IgG, IgA, and neutralizing antibody levels after BNT162b2 vaccination were lower compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.
format	article
author	Mohammad Shehab Mohamed Abu-Farha Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Jehad Abubaker Fahd Almulla
author_facet	Mohammad Shehab Mohamed Abu-Farha Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Jehad Abubaker Fahd Almulla
author_sort	Mohammad Shehab
title	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
title_short	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
title_full	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
title_fullStr	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
title_full_unstemmed	Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
title_sort	immunogenicity of bnt162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6f581808a6e84b749718e82f308ceecb
work_keys_str_mv	AT mohammadshehab immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT mohamedabufarha immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT fatemaalrashed immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT ahmadalfadhli immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT khaznaalotaibi immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT abdullahalsahli immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT thangavelalphonsethanaraj immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT arshadchannanath immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT hamadali immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT jehadabubaker immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy AT fahdalmulla immunogenicityofbnt162b2vaccineinpatientswithinflammatoryboweldiseaseoninfliximabcombinationtherapyamulticenterprospectivestudy
_version_	1718411685025284096

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Ejemplares similares